Piramal Pharma Takes Significant Steps Towards Sustainable Operations with Emissions Reduction and Enhanced Renewable Energy Usage
Piramal Pharma Limited is making remarkable strides in its sustainability efforts, as detailed in its recent report covering 2025-2026. The company, recognized as a leader in the pharmaceutical industry, has achieved a notable 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared to the previous year. Alongside this reduction, they have successfully increased their renewable energy usage to 41% of their total energy consumption across operations. This achievement marks a significant milestone on Piramal Pharma's journey toward decarbonization, aligning with the Science Based Targets initiative (SBTi).
The importance of environmental responsibility was further emphasized by management in the report's release, stating that sustainability not only serves as a corporate responsibility but also as a catalyst for innovation, resilience, and long-term growth. According to Nandini Piramal, Chairperson of Piramal Pharma Limited, the company sees sustainability as integral to its business model, influencing quality, digital capabilities, and community engagement.
Beyond emissions reduction, Piramal Pharma has made substantial efforts in waste and resource management. For instance, the company successfully redirected 65% of its total waste towards recycling efforts. They also highlighted an impressive milestone in water resource management, assisting in the recycling and reusing of 263,000 kiloliters of sweet water. These initiatives are part of a broader sustainability agenda, emphasizing responsible environmental actions and continuing improvements along sustainability metrics.
Quality and operational excellence remain a top priority for Piramal, corroborated by the report which notes zero observations during three separate USFDA inspections - a testament to the rigorous standards enforced across its operational sites. The successful completion of a significant number of quality audits and inspections underlines the company’s commitment to maintaining high compliance and safety standards within its global manufacturing network.
In addition, Piramal Pharma is investing $90 million into expanding its advanced therapeutic capabilities, which reflects its commitment to innovation and enhancement in pharmaceutical practices and production. This substantial investment will likely bolster the company's position in complex hospital generics through its subsidiaries, such as Piramal Critical Care, while continuing to grow its healthcare solutions portfolio.
During the reporting period, the company emphasized governance and employee welfare by ensuring no data breaches or corruption incidents were recorded. They maintained a 100% participation rate in Environmental, Social, and Governance (ESG) training and enforced a strict Code of Conduct for all employees, reinforcing a culture of ethical responsibility and community involvement.
Diversity and inclusion have also been focal points, with women holding 30% of board positions and comprising 20.1% of the global workforce, showcasing progress toward creating a more equitable workplace. Furthermore, 38% of the company's critical suppliers have undergone sustainability rating assessments, highlighting the integrity of their supply chain.
As part of its commitment to community development, Piramal Pharma has invested nearly 89.8 million rupees in corporate social responsibility initiatives that have positively impacted almost 1.8 million individuals through health and educational programs in aspirational districts. These efforts solidify their dedication to enhancing community welfare and strengthening stakeholder engagement.
The sustainability report embodies Piramal Pharma's long-term vision toward operational resilience, quality, responsible practices, and stakeholder focus. With over 50 time-bound sustainability goals across 17 priority areas, the report aligns with global standards such as the GRI, SASB, and UNGC frameworks, underscoring the organization’s dedication to sustainable growth and responsible business practices.
Looking forward, Piramal Pharma is committed to translating its sustainability ambitions into tangible actions, striving to enhance health outcomes while building stronger communities and delivering lasting value to all stakeholders. As they continue their forward momentum, the organization remains poised on the forefront of innovation and sustainable development in the pharmaceutical sector.
The importance of environmental responsibility was further emphasized by management in the report's release, stating that sustainability not only serves as a corporate responsibility but also as a catalyst for innovation, resilience, and long-term growth. According to Nandini Piramal, Chairperson of Piramal Pharma Limited, the company sees sustainability as integral to its business model, influencing quality, digital capabilities, and community engagement.
Beyond emissions reduction, Piramal Pharma has made substantial efforts in waste and resource management. For instance, the company successfully redirected 65% of its total waste towards recycling efforts. They also highlighted an impressive milestone in water resource management, assisting in the recycling and reusing of 263,000 kiloliters of sweet water. These initiatives are part of a broader sustainability agenda, emphasizing responsible environmental actions and continuing improvements along sustainability metrics.
Quality and operational excellence remain a top priority for Piramal, corroborated by the report which notes zero observations during three separate USFDA inspections - a testament to the rigorous standards enforced across its operational sites. The successful completion of a significant number of quality audits and inspections underlines the company’s commitment to maintaining high compliance and safety standards within its global manufacturing network.
In addition, Piramal Pharma is investing $90 million into expanding its advanced therapeutic capabilities, which reflects its commitment to innovation and enhancement in pharmaceutical practices and production. This substantial investment will likely bolster the company's position in complex hospital generics through its subsidiaries, such as Piramal Critical Care, while continuing to grow its healthcare solutions portfolio.
During the reporting period, the company emphasized governance and employee welfare by ensuring no data breaches or corruption incidents were recorded. They maintained a 100% participation rate in Environmental, Social, and Governance (ESG) training and enforced a strict Code of Conduct for all employees, reinforcing a culture of ethical responsibility and community involvement.
Diversity and inclusion have also been focal points, with women holding 30% of board positions and comprising 20.1% of the global workforce, showcasing progress toward creating a more equitable workplace. Furthermore, 38% of the company's critical suppliers have undergone sustainability rating assessments, highlighting the integrity of their supply chain.
As part of its commitment to community development, Piramal Pharma has invested nearly 89.8 million rupees in corporate social responsibility initiatives that have positively impacted almost 1.8 million individuals through health and educational programs in aspirational districts. These efforts solidify their dedication to enhancing community welfare and strengthening stakeholder engagement.
The sustainability report embodies Piramal Pharma's long-term vision toward operational resilience, quality, responsible practices, and stakeholder focus. With over 50 time-bound sustainability goals across 17 priority areas, the report aligns with global standards such as the GRI, SASB, and UNGC frameworks, underscoring the organization’s dedication to sustainable growth and responsible business practices.
Looking forward, Piramal Pharma is committed to translating its sustainability ambitions into tangible actions, striving to enhance health outcomes while building stronger communities and delivering lasting value to all stakeholders. As they continue their forward momentum, the organization remains poised on the forefront of innovation and sustainable development in the pharmaceutical sector.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.